A case for immunosuppression for myoblast transplantation in duchenne muscular dystrophy.
作者信息
Tremblay Jacques P, Skuk Daniel, Palmieri Benjamino, Rothstein David M
机构信息
Centre de Recherche du Centre Hospitalier Universitaire de Québec et Université Laval, Canada.
出版信息
Mol Ther. 2009 Jul;17(7):1122-4. doi: 10.1038/mt.2009.125.
Abstract
摘要
相似文献
1
A case for immunosuppression for myoblast transplantation in duchenne muscular dystrophy.
Mol Ther. 2009 Jul;17(7):1122-4. doi: 10.1038/mt.2009.125.
2
Assessment of a symptomatic Duchenne muscular dystrophy carrier 20 years after myoblast transplantation from her asymptomatic identical twin sister.
Neuromuscul Disord. 2013 Jul;23(7):575-9. doi: 10.1016/j.nmd.2013.04.007. Epub 2013 May 31.
3
The role of immunosuppression in gene- and cell-based treatments for duchenne muscular dystrophy.
Mol Ther. 2007 Jun;15(6):1040-1. doi: 10.1038/sj.mt.6300194.
4
In defense of myoblast transplantation research in preteens with Duchenne muscular dystrophy.
Pediatr Transplant. 2010 Nov;14(7):809-12. doi: 10.1111/j.1399-3046.2009.01235.x. Epub 2010 Aug 5.
5
Cell therapy in Duchenne muscular dystrophy treatment: clinical trials overview.
Crit Rev Eukaryot Gene Expr. 2015;25(1):1-11. doi: 10.1615/critreveukaryotgeneexpr.2015011074.
6
[Co-transplantation of myoblasts and schwann cells in the therapy of Duchenne muscular dystrophy].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 Jan;42(1):101-5.
7
Clarifying misconceptions about myoblast transplantation in myology.
Mol Ther. 2014 May;22(5):897-8. doi: 10.1038/mt.2014.57.
8
Induction of CCAAT/Enhancer-Binding Protein β Expression With the Phosphodiesterase Inhibitor Isobutylmethylxanthine Improves Myoblast Engraftment Into Dystrophic Muscle.
Stem Cells Transl Med. 2016 Apr;5(4):500-10. doi: 10.5966/sctm.2015-0169. Epub 2016 Mar 3.
9
Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy.
Pediatr Transplant. 2010 Nov;14(7):813-9. doi: 10.1111/j.1399-3046.2010.01377.x.
10
Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs.
Mol Ther. 2008 Jul;16(7):1340-6. doi: 10.1038/mt.2008.102. Epub 2008 May 27.
引用本文的文献
1
Hypoxia-induced PD-L1 expression and modulation of muscle stem cell allograft rejection.
Front Pharmacol. 2024 Nov 1;15:1471563. doi: 10.3389/fphar.2024.1471563. eCollection 2024.
2
Cell Therapy Strategies on Duchenne Muscular Dystrophy: A Systematic Review of Clinical Applications.
Stem Cell Rev Rep. 2024 Jan;20(1):138-158. doi: 10.1007/s12015-023-10653-8. Epub 2023 Nov 13.
3
Potential Therapies Using Myogenic Stem Cells Combined with Bio-Engineering Approaches for Treatment of Muscular Dystrophies.
Cells. 2019 Sep 11;8(9):1066. doi: 10.3390/cells8091066.
4
Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies.
Trends Mol Med. 2019 Sep;25(9):803-816. doi: 10.1016/j.molmed.2019.07.004.
5
The skeletal muscle satellite cell: still young and fascinating at 50.
J Histochem Cytochem. 2011 Dec;59(12):1041-59. doi: 10.1369/0022155411426780.
6
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.
Am J Pathol. 2011 Jul;179(1):12-22. doi: 10.1016/j.ajpath.2011.03.050. Epub 2011 May 23.
本文引用的文献
1
Drug targets in cytomegalovirus infection.
Infect Disord Drug Targets. 2009 Apr;9(2):201-22. doi: 10.2174/187152609787847758.
2
Current and future standards in treatment of myasthenia gravis.
Neurotherapeutics. 2008 Oct;5(4):535-41. doi: 10.1016/j.nurt.2008.08.011.
3
Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
Rheumatology (Oxford). 2008 Nov;47(11):1678-81. doi: 10.1093/rheumatology/ken335. Epub 2008 Aug 27.
4
Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?
Haematologica. 2007 Nov;92(11):1447-50. doi: 10.3324/haematol.11272.
5
Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus.
Am J Nephrol. 2006;26(6):544-51. doi: 10.1159/000097864. Epub 2006 Dec 7.
6
First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up.
Neuromuscul Disord. 2007 Jan;17(1):38-46. doi: 10.1016/j.nmd.2006.10.003. Epub 2006 Dec 4.
7
Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells.
J Neuropathol Exp Neurol. 2006 Apr;65(4):371-86. doi: 10.1097/01.jnen.0000218443.45782.81.
8
Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
Am J Transplant. 2005 Dec;5(12):2894-900. doi: 10.1111/j.1600-6143.2005.01115.x.
9
Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.
BMJ. 2005 Oct 8;331(7520):810. doi: 10.1136/bmj.38569.471007.AE. Epub 2005 Sep 12.
10
Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells.
Mol Ther. 2004 Mar;9(3):475-82. doi: 10.1016/j.ymthe.2003.11.023.
Zotero 插件